Malunga-nomhlaza / unyango / ulingo lweklinikhi / isifo / umhlaza womhlaza / unyango

Unyango lweeKlinikhi zovavanyo lweCancer yoMhlaza

Uvavanyo lwezonyango zizifundo zophando ezibandakanya abantu. Uvavanyo lwezonyango kolu luhlu lonyango lonyango lomhlaza. Zonke izilingo ezikuluhlu ziyaxhaswa yi-NCI.

Ulwazi olusisiseko lwe-NCI malunga nolingo lweklinikhi luchaza iintlobo kunye nezigaba zovavanyo kunye nendlela ezenziwa ngayo. Uvavanyo lwezonyango lujonga iindlela ezintsha zokuthintela, ukufumanisa, okanye ukunyanga izifo. Unokufuna ukucinga ngokuthatha inxaxheba kuvavanyo lweklinikhi. Thetha nogqirha wakho ngoncedo ekunqumeni ukuba ikulungele na.

Iimvavanyo 1-23 ze-23

I-Nivolumab emva koNyango lweNdlela eManyanisiweyo yokuNyanga abaguli abanomngcipheko ophezulu weSigaba II-IIIB soMhlaza.

Isigaba sesi-II solingo lwezonyango esingahleliwe senziwa njani i-nivolumab emva konyango oludibeneyo lokunyanga olusebenza ekunyangeni abaguli abanomngcipheko omkhulu womhlaza wesigaba II-IIIB somhlaza. I-Immunotherapy ene-monoclonal antibodies, efana ne-nivolumab, inokunceda amajoni omzimba ahlasele umhlaza, kwaye inokuphazamisa amandla eeseli zethumba ukukhula kunye nokusasazeka.

Indawo: Iindawo ezingama-744

I-Nivolumab kunye okanye ngaphandle kwe-Ipilimumab ekunyangeni abaguli abane-Refractory Metastatic Anal Canal Cancer

Isigaba sesibini sokuvavanywa kwesilingo sendlela esebenza ngayo i-nivolumab kunye okanye ngaphandle kwe-ipilimumab ekunyangeni abaguli abanomhlaza womhlaza ongaphendulanga kunyango lwangaphambili (elichasayo) kwaye lasasazeka kwezinye iindawo emzimbeni (metastatic). I-Immunotherapy ene-monoclonal antibodies, enje nge-nivolumab kunye ne-ipilimumab, inokunceda amajoni omzimba ahlasele umhlaza, kwaye inokuphazamisa amandla eeseli zethumba ukukhula kunye nokusasazeka.

Indawo: Iindawo ezingama-42

I-Nivolumab kunye ne-Ipilimumab ekunyangeni abaguli abane-HIV Amanyaniswa abuye abuye okanye abonakalise i-Classical Hodgkin Lymphoma okanye ii-Tumors eziQinisekileyo eziMetastatic okanye azinakususwa ngotyando

Eli nqanaba ndilingwa kuvavanyo lweziphumo ebezingalindelekanga kunye nethamo elifanelekileyo le-nivolumab xa inikwa i-ipilimumab ekunyangeni abaguli abane-virus ye-immunodeficiency virus (HIV) ehambelana ne-Hodgkin lymphoma ehambelana nokubuyela emva kwexesha lokuphucula okanye elingaphenduliyo kunyango, okanye amathumba aqinileyo sele zisasazekile kwezinye iindawo emzimbeni okanye azinakususwa ngotyando. I-Immunotherapy ene-monoclonal antibodies, njenge-ipilimumab kunye ne-nivolumab, inokunceda amajoni omzimba ahlasele umhlaza, kwaye inokuphazamisa ukubanakho kweeseli zethumba ukukhula kunye nokusasazeka. I-Ipilimumab yintsholongwane esebenza ngokuchasene nemolekyuli ebizwa ngokuba yi-cytotoxic T-lymphocyte antigen 4 (CTLA-4). I-CTLA-4 ilawula icandelo lamajoni akho omzimba ngokuwavala. I-Nivolumab luhlobo lwe-antibody ekhethekileyo yokufa kweseli okucwangcisiweyo kwabantu 1 (PD-1), iprotheni ejongene nokutshatyalaliswa kweeseli zomzimba. Ukunika i-ipilimumab nge-nivolumab kunokusebenza ngcono ekunyangeni abaguli abane-HIV enxulumene ne-Hodgkin lymphoma okanye i-tumors eqinileyo xa kuthelekiswa ne-ipilimumab ene-nivolumab yodwa.

Indawo: Iindawo ezingama-28

Isifundo seXmAb®20717 kwiziFundo ngeeThumba eziQinisekileyo eziQhelekileyo

Esi sisiGaba 1, idosi ezininzi, ukunyuka kwesifundo sokunyuka kwedosi ukuchaza i-MTD / RD kunye nerejimeni yeXmAb20717, ukuchaza ukhuseleko kunye nokunyamezelana, ukuvavanya i-PK kunye ne-immunogenicity, kunye nokuvavanya kwangaphambili umsebenzi wokuchasana nethumba weXmAb20717 kwizifundo ezikhethiweyo amathumba aqinileyo aqhubele phambili.

Indawo: Iindawo ezili-15

Uphononongo lophando lwe-Immuno-therapy lokuphanda ukhuseleko kunye nokusebenza kweNivolumab, kunye nonyango lweNivolumab yokuDibanisa kwiiThumba ezinxulumene neNtsholongwane

Injongo yolu phononongo ukuphanda ukhuseleko kunye nokusebenza kwe-nivolumab, kunye nivolumab yonyango yokudibanisa, ukunyanga abaguli abanamathumba ahambelana nentsholongwane. Iintsholongwane ezithile zaziwa ukuba zidlala indima ekwakheni ithumba kunye nokukhula. Olu phononongo luza kuphanda iziphumo zamachiza okufunda, kwizigulana ezinezi ndidi zilandelayo zamathumba. Uhlobo lwethumba - Umhlaza weSeli kaMerkel - Umhlaza wePenile-Awusabhalisi olu hlobo lwethumba - Umhlaza welungu lobufazi kunye nomhlaza-Awusalubhalisi olu hlobo lwethumba - Umhlaza weNasopharyngeal - Awusalubhalisi olu hlobo lwethumba - Intloko kunye nomhlaza womqala - Awusabhalisi olu hlobo lwethumba

Indawo: Iindawo ezili-10

Isifundo sePembrolizumab (MK-3475) kuBathathi-nxaxheba abaneZisu eziPhucukileyo zeSolid (MK-3475-158 / KEYNOTE-158)

Kolu phando, abathathi-nxaxheba abaneentlobo ezininzi zokuqhubela phambili (okungenakuphikwa kunye / okanye kwe-metastatic) amathumba aqinileyo aqhubekileyo kunyango olusemgangathweni lokunyanga aya kunyangwa nge-pembrolizumab.

Indawo: Iindawo ezi-8

I-High-Dose-Rate Rate Brachytherapy kunye neChemotherapy ekunyangeni abaguli abanokuphinda babekhona okanye okushiyekileyo kwiRectal okanye kwiCancer Cancer ephantsi koLawulo olungasebenziyo.

Eli nqanaba ndilingwa kuvavanyo lweziphumo ebezingalindelekanga kunye nethamo elifanelekileyo le-brachytherapy yedosi ephezulu xa unikwa kunye nechemotherapy ekunyangeni abaguli abanomhlaza wamanqatha okanye womhlaza obuyileyo okanye othe wanda kwaye awunakuphathwa ngotyando. I-Brachytherapy, ekwabizwa ngokuba lonyango lwangaphakathi lwemitha, isebenzisa izinto ezinemitha ye-radio ezibekwe ngqo okanye kufutshane nethumba ukubulala iiseli zesisu. Ireyithi yedosi ephezulu (i-HDR) brachytherapy isebenzisa izinto ezinemitha ye-radio ukuhambisa idosi ephezulu yemitha ngexesha elincinci kwithumba. Isenokuthumela nemitha encinci kwimisipha ekufuphi kwaye inokunciphisa umngcipheko weziphumo ebezingalindelekanga. Iziyobisi ezisetyenziswa kwi-chemotherapy, ezinje nge-capecitabine kunye ne-fluorouracil, zisebenza ngeendlela ezahlukeneyo ukunqanda ukukhula kweeseli zethumba, nokuba kungokubulala iiseli, ngokuzinqanda zisahlule, okanye ngokuzinqanda zisasazeke.

Indawo: Iindawo ezi-6

I-Pembrolizumab ekunyangeni abaguli abane-Metastatic okanye i-Cancer e-Advanced Advanced Cancer engenakususwa ngugqirha.

Isigaba sesibini sokuvavanywa kwesilingo sokuba isebenza njani i-pembrolizumab ekunyangeni abaguli abanomhlaza wangasemva osasazeke kwezinye iindawo emzimbeni okanye osasazeke kwindawo yawo yoqobo yokukhula ukuya kwizicubu ezikufuphi okanye i-lymph node kwaye ayinakususwa ngotyando. I-Immunotherapy ene-monoclonal antibodies, enjenge-pembrolizumab, inokunceda amajoni omzimba ahlasele umhlaza, kwaye inokuphazamisa ukubanakho kweeseli zethumba ukukhula kunye nokusasazeka.

Indawo: Iindawo ezi-5

Utyando kunyango lwezigulana ezinamazinga okuqala ohlalutyo Canal okanye umhlaza wePerianal kunye ne-HIV

Esi sigaba sesi-II sifundo solingo lotyando ekunyangeni abaguli abanomngxunya wamanzi okanye umhlaza weperianal omncinci kwaye awusasazekanga ngokunzulu kwizicubu nakwintsholongwane ye-HIV. Utyando lwasekhaya lunokuba lunyango olukhuselekileyo oluneziphumo ebezingalindelekanga ezimbalwa kunezotyando olukhulu okanye imitha kunye nonyango ngamayeza.

Indawo: Iindawo ezi-5

Uvavanyo lokufumana kunye nokuphanda ngeDosi ekhuselekileyo yeZinto eziTsha (i-BI 754091) yeZigulana ezinamathumba aqinileyo.

Eyona njongo iphambili yenqanaba lokunyuka kwethamo kukumisela ukhuseleko kunye nokunyamezeleka, kunye nokumisela i-Maximum Tolerated Dose kunye / okanye iNqanaba eliCetyiswayo leSigaba 2 (RP2D) le-BI 754091 kwisiseko sezigulana ezinomda wokunciphisa idosi. iityhefu (i-DLTs) kwizigulana ezinesifo esibi esonyuliweyo. Ukhuseleko kunye nokunyamezelana kuya kuvavanywa ngokujonga ukwenzeka kweziganeko ezigwenxa (AEs), ii-AEs ezinzulu (SAE), kunye nokungaqheleki kweparameter yelabhoratri, kunye notshintsho lweempawu ezibalulekileyo. Iinjongo zesekondari kukumiselwa kweprofayili ye-PK ye-BI 754091 emva kwedosi enye kunye ne-BI 754091, kunye novavanyo lokuqala lomsebenzi we-antitumour. Kwinxalenye yokwandiswa kwethamo kwetyala, ezona njongo ziphambili kukuvavanya ukhuseleko, ukusebenza ngempumelelo, iprofayile yePK,

Indawo: Indawo ezi-3

I-Stereotactic Radiosurgery ekunyangeni abaguli abanesifo se-Oligometastatic

Isigaba sesibini sokuvavanywa kwesilingo sisebenza ngendlela eyiyo i-stereotactic radiosurgery ekunyangeni abaguli abanomhlaza osasazeke kwiindawo ezi-5 okanye ezimbalwa emzimbeni kwaye kubandakanya amalungu amathathu okanye ambalwa (isifo se-oligometastatic). I-radiosurgery ye-stereotactic, ekwabizwa ngokuba lonyango lwe-radiation stereotactic, lunyango olukhethekileyo lokuhambisa imitha ehambisa idosi enye, ephezulu yemitha ngqo kwi-tumor kwaye inokubulala iiseli ezininzi zethumba kwaye ibangele umonakalo omncinci kwizicubu eziqhelekileyo.

Indawo: Indawo ezi-3

Isifundo se-INCMGA00012 kwi-Squamous Carcinoma ye-Can Canal elandela iPlatinum-based Chemotherapy (POD1UM-202)

Injongo yolu phononongo kukuvavanya ukusebenza kwe-INCMGA00012 kubathathi-nxaxheba abane-carcinoma ye-squalous ye-squalous ye-anal canal (SCAC) eqhubele phambili emva kwekhemotherapy esekwe kwiplatinam.

Indawo: Iindawo ezi-4

I-Artesunate ekunyangeni abaguli abane-Anal-Intraepithelial Neoplasia ePhakamileyo

Eli nqanaba ndilingwa kuvavanyo lweziphumo ebezingalindelekanga kunye nethamo elifanelekileyo le-artesunate ekunyangeni abaguli abane-grade ye-anal intraepithelial neoplasia. I-anal intraepithelial neoplasia ziiseli zangaphambi kwexesha ezinokuthi okanye zingabi ngumhlaza kwikamva. Uninzi lotshintsho olukhokelela kumhlaza lubangelwa yipapillomavirus yabantu (HPV). I-Artesunate inokubulala iiseli ezosulelwe yi-HPV.

Indawo: Indawo ezi- 2

Isifundo se-LY3434172, iPD-1 kunye ne-PD-L1 Bispecific Antibody, kwiCancer ephezulu

Eyona njongo iphambili yolu phononongo kukuvavanya ukhuseleko kunye nokunyamezeleka kwesiyobisi se-LY3434172, i-PD-1 / PD-L1 bispecific antibody, kubathathi-nxaxheba abanezilonda eziqinileyo eziqhubele phambili.

Indawo: Iziko loMhlaza le-And Anderson, eHouston, eTexas

I-SL-279252 (PD1-Fc-OX40L) kwizihloko ezinezidumbu eziQinisekileyo eziQinisekileyo okanye iiLymphomas

Eli linqanaba lokuqala lokuqala ebantwini, kwilebheli evulekileyo, kwiziko elinamaziko amaninzi, ukunyuka kwedosi kunye nophononongo lokonyusa idosi ukuvavanya ukhuseleko, ukunyamezeleka, i-PK, umsebenzi wokuchasana nethumba kunye nefuthe le-pharmacodynamic ye-SL-279252 kwizifundo ezinamathumba aqinileyo okanye i-lymphomas .

Indawo: Iziko loMhlaza le-And Anderson, eHouston, eTexas

I-LET-IMPT kunye ne-Chemotherapy esemgangathweni ekunyangeni abaguli abanesigaba esitsha sokuchonga isifo se-I-III seCan Canal Squamous Cell Cancer

Esi sigaba sesibini solingo sijonga iziphumo ebezingalindelekanga ze-LET-IMPT kunye ne-chemotherapy esemgangathweni, kwaye basebenza kakuhle njani ekunyangeni abaguli abanesifo esandula ukufumanisa isifo se-I-III canal squamous cell somhlaza. I-LET-IMPT luhlobo lonyango lwe-radiation olusebenzisa amandla amakhulu eproton "beamlets" "ukupeyinta" idosi yemitha ekujoliswe kuyo kwaye inokunceda ukubulala iiseli zethumba kunye nokunciphisa amathumba. Ukunika i-LET-IMPT kunye ne-chemotherapy esemgangathweni kunokusebenza ngcono ekunyangeni abaguli abanomhlaza wesibeleko somhlaza weseli.

Indawo: Iziko loMhlaza le-And Anderson, eHouston, eTexas

I-VGX-3100 kunye ne-Electroporation ekunyangeni abaguli abane-HIV-Positive High-Grade Anal Lesions

Isigaba sesi-II silinganisa ukuba ipapillomavirus (HPV) ye-deoxyribonucleic acid (DNA) yeplasmids yonyango lokugonya i-VGX-3100 (VGX-3100) kunye nomsebenzi wokunyanga abantu abagulayo abanesifo se-immunodeficiency virus (HIV). Amachiza enziwe nge-DNA anokunceda umzimba ukuba wakhe impendulo efanelekileyo yomzimba yokuzikhusela ekubulaleni iiseli zethumba. Ukufakwa kombane kunceda ii-pores kwiiseli zomzimba wakho ukuthatha ichiza ukomeleza impendulo yomzimba wakho. Ukunika i-VGX-3100 kunye nokufakwa kwezinto kunye kunokusebenza ngcono ekunyangeni abaguli abanezilonda ezikwinqanaba eliphezulu.

Indawo: Indawo ezi- 2

I-DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Therapeutic Vaccine INO-3112 kunye neDurvalumab ekuNyangeni abaguli abanomhlaza onxulumene nawo okanye weMetastatic Human Papillomavirus.

Isigaba sesibini solingo sifundo ukuba i-deoxyribonucleic acid (DNA) yeplasmid-encoding interleukin-12 / human papillomavirus (HPV) ye-DNA plasmids yeyeza lokunyanga INO-3112 kunye nomsebenzi we-durvalumab ekunyangeni abaguli abanomhlaza we-papillomavirus ezinomdlavuza ezibuyileyo okanye zisasazeke kwezinye indawo emzimbeni. Izitofu ezenziwe kwintsholongwane eguqulweyo yemfuza zinokunceda umzimba wakhe impendulo efanelekileyo yomzimba yokuzikhusela ekubulaleni iiseli zethumba. Unyango lwe-Immunotherapy olunee-antibodies ze-monoclonal, ezinjenge-durvalumab, lunokunceda amajoni omzimba ahlasele umhlaza, kwaye unokuphazamisa amandla eeseli zethumba ukukhula kunye nokusasazeka. Ukunika i-DNA plasmid-encoding interleukin-12 / HPV DNA plasmids yeyeza lokunyanga i-INO-3112 kunye ne-durvalumab inokusebenza ngcono ekunyangeni abaguli abanomhlaza we-papillomavirus womhlaza.

Indawo: Iziko loMhlaza le-And Anderson, eHouston, eTexas

I-M7824 kwizifundo ezine-HPV eziManyeneyo

Imvelaphi: E-United States, unyaka ngamnye zingaphezulu kwama-30,000 iimeko ze-human papillomavirus (HPV) ezinxulumene nomhlaza. Eminye yale mihlaza ihlala inganyangeki kwaye ayiphuculwa ngonyango oluqhelekileyo. Abaphandi bafuna ukubona ukuba ngaba ichiza elitsha i-M7824, elijolise kwaye livimbe indlela ethintela amajoni omzimba ekulweni umhlaza ngokufanelekileyo anganciphisa amathumba kubantu abanomhlaza othile we-HPV. Iinjongo: Ukujonga ukuba ichiza i-M7824 ibangela ukuba izicwili zinciphe. Ukufaneleka: Abantu abadala abaneminyaka eli-18 nangaphezulu abanomhlaza onxulumene nosulelo lwe-HPV. Uyilo: Abathathi-nxaxheba baya kuvavanywa ngembali yezonyango kunye novavanyo lomzimba. Baza kujonga iimpawu zabo kunye nendlela abenza ngayo imisebenzi yesiqhelo. Baya kuba nemibala yomzimba. Baya kunika iisampulu zegazi kunye nomchamo. Baya kuba nesampulu yamathambo abo ethumba athathwe ukuba elinye alifumaneki. Abathathi-nxaxheba baya kuba ne-electrocardiogram yokuvavanya iintliziyo zabo. Emva koko baya kufumana iyeza lokufunda ngombhobho omncinci kumthambo wengalo. Abathathi-nxaxheba baya kufumana iyeza rhoqo kwiiveki ezi-2 ngamaxesha angama-26 (unyaka omnye). Le khosi eyi-1. Emva kwekhosi, abathathi-nxaxheba baya kubekwa esweni kodwa abayikuthatha iyeza lokufunda. Ukuba imeko yabo iya isiba mandundu, baya kuqala enye ikhosi kunye neziyobisi. Le nkqubo inokuphindaphindwa amaxesha amaninzi njengoko kufuneka. Unyango luya kuyeka xa umntu ethatha inxaxheba eneziphumo ebezingalindelekanga ezimbi okanye iyeza liyeke ukusebenza. Kulo lonke uphando, abathathi-nxaxheba baya kuphinda ezinye okanye zonke iimvavanyo zokuhlola. Emva kokuba abathathi-nxaxheba bayeke ukuthatha iziyobisi, baya kuba notyelelo olulandelayo kunye nokuphinda kuvavanyo lokuhlola. Baza kufumana iifowuni zokulandelela rhoqo. ... Emva koko baya kufumana iyeza lokufunda ngombhobho omncinci kumthambo wengalo. Abathathi-nxaxheba baya kufumana iyeza rhoqo kwiiveki ezi-2 ngamaxesha angama-26 (unyaka omnye). Le khosi eyi-1. Emva kwekhosi, abathathi-nxaxheba baya kubekwa esweni kodwa abayikuthatha iyeza lokufunda. Ukuba imeko yabo iya isiba mandundu, baya kuqala enye ikhosi kunye neziyobisi. Le nkqubo inokuphindaphindwa amaxesha amaninzi njengoko kufuneka. Unyango luya kuyeka xa umntu ethatha inxaxheba eneziphumo ebezingalindelekanga ezimbi okanye iyeza liyeke ukusebenza. Kulo lonke uphando, abathathi-nxaxheba baya kuphinda ezinye okanye zonke iimvavanyo zokuhlola. Emva kokuba abathathi-nxaxheba bayeke ukuthatha iziyobisi, baya kuba notyelelo olulandelayo kunye nokuphinda kuvavanyo lokuhlola. Baza kufumana iifowuni zokulandelela rhoqo. ... Emva koko baya kufumana iyeza lokufunda ngombhobho omncinci kumthambo wengalo. Abathathi-nxaxheba baya kufumana iyeza rhoqo kwiiveki ezi-2 ngamaxesha angama-26 (unyaka omnye). Le khosi eyi-1. Emva kwekhosi, abathathi-nxaxheba baya kubekwa esweni kodwa abayikuthatha iyeza lokufunda. Ukuba imeko yabo iya isiba mandundu, baya kuqala enye ikhosi kunye neziyobisi. Le nkqubo inokuphindaphindwa amaxesha amaninzi njengoko kufuneka. Unyango luya kuyeka xa umntu ethatha inxaxheba eneziphumo ebezingalindelekanga ezimbi okanye iyeza liyeke ukusebenza. Kulo lonke uphando, abathathi-nxaxheba baya kuphinda ezinye okanye zonke iimvavanyo zokuhlola. Emva kokuba abathathi-nxaxheba bayeke ukuthatha iziyobisi, baya kuba notyelelo olulandelayo kunye nokuphinda kuvavanyo lokuhlola. Baza kufumana iifowuni zokulandelela rhoqo. ... abathathi-nxaxheba baya kujongwa kodwa abazukuthatha iziyobisi. Ukuba imeko yabo iya isiba mandundu, baya kuqala enye ikhosi kunye neziyobisi. Le nkqubo inokuphindaphindwa amaxesha amaninzi njengoko kufuneka. Unyango luya kuyeka xa umntu ethatha inxaxheba eneziphumo ebezingalindelekanga ezimbi okanye iyeza liyeke ukusebenza. Kulo lonke uphando, abathathi-nxaxheba baya kuphinda ezinye okanye zonke iimvavanyo zokuhlola. Emva kokuba abathathi-nxaxheba beyekile ukuthatha ichiza, baya kuba notyelelo olulandelayo kunye nokuphinda kuvavanyo lokuvavanya. Baza kufumana iifowuni zokulandelela rhoqo. ... abathathi-nxaxheba baya kujongwa kodwa abazukuthatha iziyobisi. Ukuba imeko yabo iya isiba mandundu, baya kuqala enye ikhosi kunye neziyobisi. Le nkqubo inokuphindaphindwa amaxesha amaninzi njengoko kufuneka. Unyango luya kuyeka xa umntu ethatha inxaxheba eneziphumo ebezingalindelekanga ezimbi okanye iyeza liyeke ukusebenza. Kulo lonke uphando, abathathi-nxaxheba baya kuphinda ezinye okanye zonke iimvavanyo zokuhlola. Emva kokuba abathathi-nxaxheba bayeke ukuthatha iziyobisi, baya kuba notyelelo olulandelayo kunye nokuphinda kuvavanyo lokuhlola. Baza kufumana iifowuni zokulandelela rhoqo. ... Emva kokuba abathathi-nxaxheba bayeke ukuthatha iziyobisi, baya kuba notyelelo olulandelayo kunye nokuphinda kuvavanyo lokuhlola. Baza kufumana iifowuni zokulandelela rhoqo. ... Emva kokuba abathathi-nxaxheba bayeke ukuthatha iziyobisi, baya kuba notyelelo olulandelayo kunye nokuphinda kuvavanyo lokuhlola. Baza kufumana iifowuni zokulandelela rhoqo. ...

Indawo: Amaziko kaZwelonke eKliniki, eBethesda, eMaldin

I-MnSOD yeMimetic BMX-001 ekunyangeni abaguli abanomhlaza womhlaza ophantsi konyango lweRadiation kunye neChemotherapy.

Eli nqanaba ndilingwa kuvavanyo lweyona dosi ilungileyo ye-MnSOD mimetic BMX-001 ukunciphisa iziphumo ebezingalindelekanga kwizigulana ezinomhlaza wamazinyo ophantsi konyango lwemitha kunye nonyango ngamayeza. Amachiza okuphelisa intsholongwane, anje nge-BMX-001, anokukhusela iiseli eziqhelekileyo kwiziphumo ze-chemotherapy ngelixa usomeleza ukubulawa kwethumba.

Indawo: IYunivesithi yaseNebraska Medical Centre, eOmaha, eNebraska

I-Atezolizumab kunye neBevacizumab ekunyangeni abaguli abanamaThumba aQhelekileyo aQinisekileyo

Isigaba sesibini sokuvavanywa kwesilingo sokuba i-atezolizumab kunye ne-bevacizumab zisebenza njani ekunyangeni abaguli abanamathumba aqinileyo anqabileyo. I-Immunotherapy ene-monoclonal antibodies, enjenge-atezolizumab kunye ne-bevacizumab, inokunceda amajoni omzimba ahlasele umhlaza, kwaye inokuphazamisa ukubanakho kweeseli zethumba ukukhula kunye nokusasazeka.

Indawo: Iziko loMhlaza le-And Anderson, eHouston, eTexas

Unyango lwe-Vaccine kunye ne-Cyclophosphamide ekunyangeni abaguli abane-HLA-A * 02 Positive Relapsed, Refractory, or Metastatic HPV16-Related Oropharyngeal, Cervical, or Anal Cancer

Esi sigaba sifundo se-Ib / II sophando lweziphumo ebezingalindelekanga kunye nedosi efanelekileyo ye-HPV16-E711-19 ye-nanomer vaccine ye-DPX-E7 kwaye ibone ukuba isebenza njani xa inikwa kunye ne-cyclophosphamide ekunyangeni abaguli abane-HLA-A * 02, ipapillomavirus yabantu 16 ( I-HPV16) enxulumene ne-oropharyngeal, yomlomo wesibeleko, okanye umhlaza wangasemva obuyileyo, awuphenduli kunyango, okanye usasazeke kwamanye amalungu omzimba. Izitofu ezenziwe kwintsholongwane eguqulweyo yemfuza zinokunceda umzimba wakhe impendulo efanelekileyo yomzimba yokuzikhusela ekubulaleni iiseli zethumba. Iziyobisi ezisetyenziswa kwi-chemotherapy, ezinje nge-cyclophosphamide, zisebenza ngeendlela ezahlukeneyo ukunqanda ukukhula kweeseli zethumba, nokuba kungokubulala iiseli, ngokuzinqanda ekwahluleni, okanye ngokuzinqanda zisasazeke. Ukunika isitofu sokugonya se-HPV16-E711-19 nanomer DPX-E7 kunye necyclophosphamide kunokusebenza ngcono ekunyangeni abaguli abane-oropharyngeal enxulumene ne-HPV16,

Indawo: IZiko loMhlaza laseDana-Farber, eBoston, eMassachusetts

I-Nivolumab kunye ne-Ipilimumab ekunyangeni abaguli abanezilonda eziqhelekileyo

Esi sigaba sesibini solingo sifundo se-nivolumab kunye ne-ipilimumab ekunyangeni abaguli abanamathumba anqabileyo. I-Immunotherapy ene-monoclonal antibodies, enje nge-nivolumab kunye ne-ipilimumab, inokunceda amajoni omzimba ahlasele umhlaza, kwaye inokuphazamisa amandla eeseli zethumba ukukhula kunye nokusasazeka. Olu vavanyo lubhalisa abathathi-nxaxheba kula maqela alandelayo ngokusekwe kwimeko: 1. Izidumba ze-Epithelial ze-nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC] , kunye ne-squamous cell carcinoma yentloko nentamo [SCCHN]) B) I-Adenocarcinoma kunye nokwahluka kwethambo lempumlo, i-sinus, kunye ne-nasopharynx (kuvaliwe ukuya kwi-07/27/2018) 2. Izidumba ze-Epithelial zamadlala amakhulu we-salivary (avaliwe ukuya kwi-03 eyongezelelweyo) / 20/2018) 3. Uhlobo lwe-salivary gland uhlobo lwentloko nentamo, imilebe, umqala, isisu, i-trachea kunye nemiphunga, isifuba kunye nenye indawo (evaliweyo ukuya kwi-accrual) 4. I-carcinoma engachazwanga yendlela yesisu (GI) 5. I-Adenocarcinoma enezinto ezahlukeneyo zamathumbu amancinci (avaliwe ukuze afikelele 05/10/2018) 6. squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. I-Fibromixoma kunye ne-low grade mucinous adenocarcinoma (pseudomixoma peritonei) ye Isihlomelo kunye ne-ovary (kuvaliwe ukuya kwi-03/20/2018) 8. Amarhala erhabaxa epancreatic kubandakanya i-acinar cell carcinoma, i-mucinous cystadenocarcinoma okanye i-serous cystadenocarcinoma. I-Pancreatic adenocarcinoma ayifanelekanga i-Intrahepatic cholangiocarcinoma (ivaliwe ngo-03/20/2018). I-Extrahepatic cholangiocarcinoma kunye ne-bile duct tumors (ivaliwe ukuya kwi-03/20/2018) 11. I-Sarcomatoid carcinoma yemiphunga 12. I-Bronchoalveolar carcinoma lung. Le meko ngoku ikwabizwa ngokuba yi-adenocarcinoma in situ, i-adenocarcinoma encinci, i-adidocarcinoma, okanye i-adenocarcinoma engenayo i-mucinous 13. Izidumba ezingenayo i-epithelial ye-ovary: A) Ithumba leseli le-germ le-ovary B) ukuya kwitraphblastic tumor: A) I-Choriocarcinoma (ivaliwe ukuya kwi-04/15/2019) 15. Transitional cell carcinoma ngaphandle kwe-renal, i-pelvis, i-ureter, okanye i-bladder (ivaliwe ngo-04 / 15/2019) 16. Ithumba leseli leemvavanyo kunye nezidumba zentsholongwane ye-extragonadal: Amathumba e-Apocrine / extramammary Isifo sikaPaget 40. I-Peritoneal mesothelioma 41. I-Basal cell carcinoma 42. Sula umhlaza weseli yomlomo wesibeleko 43. I-Esthenioneuroblastoma 44. I-endometrial carcinosarcoma (amathumba axubileyo aseMullerian) (ivaliwe yanda) 45. Cima iseli yomhlaza wesibeleko endometrium 46. Sula iseli umhlaza we-ovari 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umhlaza we-Gallbladder 49. Iseli encinci ye-carcinoma ye-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 yonyusa amathumba 51. I-Angiosarcoma 52. Inqanaba eliphezulu le-neuroendocrine carcinoma (ithumba lepancreatic neuroendocrine [PNET] kufuneka ubhalise kwiQela lama-22; I-Prostatic neuroendocrine carcinomas kufuneka ibhalise kwiQela lama-53). Umhlaza wemiphunga wamaseli amancinci akafanelekanga 53. Unyango-oluvela kwiseli encinci ye-neuroendocrine umhlaza webele wendlala (t-SCNC) Cima umhlaza wesibeleko somlomo wesibeleko 43. Esthenioneuroblastoma 44. I-Endometrial carcinosarcoma (amathumba axubeneyo aseMullerian) (avaliwe ukuya kwi-accrual) 45. Cima iseli yomhlaza wesibeleko se-endometrium 46. Sula umhlaza weseli ovarian 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umhlaza we-Gallbladder 49. Omncinci iseli carcinoma ye-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 yonyusa amathumba 51. I-Angiosarcoma 52. I-neuroendocrine carcinoma ekumgangatho ophezulu (ityhefu yepancreatic neuroendocrine [PNET] kufuneka ibhaliswe kwiQela lama-22; i-Prostatic neuroendocrine carcinomas kufuneka ibhaliswe kwiQela lama-53). Umhlaza wemiphunga wamaseli amancinci akafanelekanga 53. Unyango-oluvela kwiseli encinci ye-neuroendocrine umhlaza webele wendlala (t-SCNC) Cima umhlaza wesibeleko somlomo wesibeleko 43. Esthenioneuroblastoma 44. I-Endometrial carcinosarcoma (amathumba axubeneyo aseMullerian) (avaliwe ukuya kwi-accrual) 45. Cima iseli yomhlaza wesibeleko se-endometrium 46. Sula umhlaza weseli ovarian 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umhlaza we-Gallbladder 49. Omncinci iseli carcinoma ye-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 yonyusa amathumba 51. I-Angiosarcoma 52. I-neuroendocrine carcinoma ekumgangatho ophezulu (ityhefu yepancreatic neuroendocrine [PNET] kufuneka ibhaliswe kwiQela lama-22; i-Prostatic neuroendocrine carcinomas kufuneka ibhaliswe kwiQela lama-53). Umhlaza wemiphunga wamaseli amancinci akafanelekanga 53. Unyango-oluvela kwiseli encinci ye-neuroendocrine umhlaza webele wendlala (t-SCNC) Cima umhlaza wesibeleko se-ovari 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umhlaza we-Gallbladder 49. Iseli encinci ye-carcinoma ye-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 yonyusa amathumba 51. I-Angiosarcoma 52. Inqanaba eliphezulu le-neuroendocrine carcinoma (ithumba lepancreatic neuroendocrine [PNET ] kufuneka babhalise kwiCohort 22; I-Prostatic neuroendocrine carcinomas kufuneka ibhalise kwiQela 53). Umhlaza wemiphunga wamaseli amancinci akafanelekanga 53. Unyango-oluvela kwiseli encinci ye-neuroendocrine umhlaza webele wendlala (t-SCNC) Cacisa umhlaza wesibeleko se-ovari 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umhlaza we-Gallbladder 49. Iseli encinci ye-carcinoma ye-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 yonyusa amathumba 51. I-Angiosarcoma 52. ] kufuneka babhalise kwiCohort 22; I-Prostatic neuroendocrine carcinomas kufuneka ibhalise kwiQela 53). Umhlaza wemiphunga wamaseli amancinci akafanelekanga 53. Unyango-oluvela kwiseli encinci ye-neuroendocrine umhlaza webele wendlala (t-SCNC) I-Prostatic neuroendocrine carcinomas kufuneka ibhalise kwiQela lama-53). Umhlaza wemiphunga wamaseli amancinci akafanelekanga 53. Unyango-oluvela kwiseli encinci ye-neuroendocrine umhlaza webele wendlala (t-SCNC) I-Prostatic neuroendocrine carcinomas kufuneka ibhalise kwiQela lama-53). Umhlaza wemiphunga wamaseli amancinci akafanelekanga 53. Unyango-oluvela kwiseli encinci ye-neuroendocrine umhlaza webele wendlala (t-SCNC)

Indawo: Iindawo ezingama-878